What they do:

Clarrio is an AI-powered real-world data platform that gives doctors continuous visibility into the lives of patients. The platform aggregates physiological, behavioural, psychological, and environmental data from wearable devices and patient-reported inputs, then uses predictive analytics to identify disease triggers, flag deterioration risks, and support clinical decision-making in real time.

Why we invested:

The continent has the highest epilepsy prevalence globally (2–3% vs. 0.5–1% elsewhere), yet African patient populations are dramatically underrepresented in clinical trials and real-world evidence datasets. Clarrio is building proprietary, high-resolution datasets from these populations and is increasingly valuable to global pharmaceutical companies seeking diverse real-world evidence for regulatory submissions. The team combines 30+ years of pharmaceutical industry experience from Merck with AI and machine learning expertise from InstaDeep, and a Microsoft partnership that provides access to hospital procurement channels across the GCC.

The Founders:

Firas Rhaiem leads Clarrio.ai’s vision, strategic direction, and global expansion. An engineer by training with an MSc in Finance, he has built a strong track record across life sciences advisory, working with leading organizations such as IBM.

Dr. Ali Frederic Ben Amor is a globally recognized neurology and pharmaceutical executive with extensive experience in medical leadership and strategic healthcare innovation. He previously served as Senior Vice President (SVP) of Neurology, Immunology & Medical Affairs at Merck, where he led international medical operations and managed a portfolio generating approximately €500 million in annual revenue.

Dr. Karim Bendhaou is a seasoned pharmaceutical strategy leader with extensive executive experience across Africa and the MENA region. As Managing Director at Merck Northwest Africa, he led large-scale operations and regional market expansion initiatives.

Active in:

Pan African